Collegeville, PA, United States of America

Sarper Toker

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Asana Biosciences, LLC. Active years: 2020.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Sarper Toker

Introduction

Sarper Toker is a notable inventor based in Collegeville, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of formulations that enhance the stability of active pharmaceutical ingredients. His work is crucial for improving the efficacy and safety of medications.

Latest Patents

Sarper Toker holds a patent for "Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient." This patent focuses on formulations that maintain the active ingredient in a substantially amorphous form after storage under predetermined conditions. The innovations described in this patent can be utilized in treating conditions related to the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways.

Career Highlights

Sarper Toker is currently associated with Asana Biosciences, LLC, where he continues to advance his research and development efforts. His expertise in pharmaceutical formulations has positioned him as a valuable asset in the industry.

Collaborations

Throughout his career, Sarper Toker has collaborated with esteemed colleagues such as Ashish Chatterji and Navnit Hargovindas Shah. These collaborations have further enriched his work and contributed to the success of various projects.

Conclusion

Sarper Toker's innovative contributions to pharmaceutical formulations demonstrate his commitment to enhancing drug stability and efficacy. His work is vital for the advancement of treatments in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…